Nexalin Technology shares are trading higher after the company announced clinical study data in major depressive disorder and publication of clinical trial results in leading scientific journal 'Brain Stimulation'

6/26/24 11:29:44 AM ET

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Get the next $NXL alert in real time by email

Get the next $NXL alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$NXL

Date	Price Target	Rating	Analyst

More analyst ratings

$NXL
Press Releases

Fastest customizable press release news feed in the world

View All

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders

HOUSTON, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), developer of Deep Intracranial Frequency Stimulation (DIFS™) technology for non-invasive deep brain stimulation, commended the recent series of bipartisan Congressional initiatives expanding federal focus on deep brain neurostimulation and related neuromodulation research within the U.S. Department of Veterans Affairs ("VA") and the National Institutes of Health ("NIH"). Nexalin's team participated in and helped shape specific portions of the legislation to expand veterans' access to emerging treatments, and commends Congress on the recent passage of appropriations packages th

2/23/26 8:18:00 AM ET

$NXL

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care

HOUSTON, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the launch of its new AI-designed virtual clinic platform, NeuroCare®, in collaboration with the University of California, San Diego. This marks the first step in deploying Nexalin's digital health ecosystem, designed to increase patient access, reduce costs, and provide long-term physician-patient care and monitoring across critical brain-health indications. This collaboration builds upon Nexalin's ongoing clinical research relationship with UC San Diego where patient enrollment has be

2/5/26 8:37:00 AM ET

$NXL

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

HOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today highlighted Nexalin's rigorous peer-reviewed clinical research validating its proprietary neurostimulation technology across multiple neurological and psychiatric conditions. Currently, Nexalin is advancing its "mood-military-memory" clinical business plan with the FDA by publishing and submitting extensive clinical data. Recent peer-reviewed and published data collectively span Insomnia and Depression (mood), traumatic brain injury and PTSD (military), Alzheimer's disease (memory),

2/2/26 8:45:00 AM ET

$NXL

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

$NXL
Leadership Updates

Live Leadership Updates

View All

Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. ("Carmi Masha"), a leading Israeli medical device distributor, to market and sell Nexalin's Gen-2 Console ("SYNC"), 15 milliamp (mA), non-invasive frequency-based neurostimulation device throughout Israel. This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin's Gen-2 SYNC device in Israel for the treatment of a var

11/13/25 9:15:00 AM ET

$NXL

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs

HOUSTON, TX, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Dr. Robert Rothstein, a pioneering expert in mental healthcare, to its Scientific Advisory Board (SAB). This addition reinforces Nexalin's strategic focus on the global mental healthcare crisis, including the treatment of Alzheimer's disease and Traumatic Brain Injury (TBI). In anticipation of the Company's new FDA submissions, Dr. Rothstein will support Nexalin's preparation of its Q-submission for a meeting with the FDA later this year. Dr. Rothstein bring

10/13/25 8:30:00 AM ET

$NXL

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin's Next Phase of Growth and Strategic Initiatives

HOUSTON, TX, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Justin Van Fleet, CPA, as Chief Financial Officer, effective August 1, 2025. Mr. Van Fleet brings more than 20 years of experience in public accounting and assurance services, most recently serving as Partner at Marcum LLP (formerly Friedman LLP). In this role, he led the firm's assurance practice and advised both publicly traded and privately held clients across a wide range of sectors including technology, life sciences, manufacturing, and distribution. He

8/1/25 8:30:00 AM ET

$NXL

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

$NXL
Financials

Live finance-specific insights

View All

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / November 1, 2024 / RedChip Companies will air interviews with LOBO EV Technologies Ltd. (NASDAQ:LOBO) and Nexalin Technology, Inc. (NASDAQ:NXL) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:LOBO EV: https://www.redchip.com/assets/access/lobo_accessNexalin: https://www.redchip.com/assets/access/nxl_accessIn an exclusive interview, Harry D. Schulman, Independent Director of LOBO EV Technologies, appears on the RedChip Small Stocks Big Money™ show on Bloomberg T

11/1/24 9:00:00 AM ET

$LOBO

$NXL

Motor Vehicles

Consumer Discretionary

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (NASDAQ:NXL) and Calidi Biotherapeutics, Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nexalin: https://www.redchip.com/assets/access/nxl_accessCalidi: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Mark White, CEO of Nexalin Technology, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate

10/25/24 9:00:00 AM ET

$CLDI

$NXL

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / July 26, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (NASDAQ:NXL) and LOBO EV Technologies Ltd. (NASDAQ:LOBO) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nexalin: https://www.redchip.com/assets/access/nxl_accessLOBO EV: https://www.redchip.com/assets/access/lobo_accessMark White, CEO of Nexalin, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Nexalin stands at the forefront of th

7/26/24 9:55:00 AM ET

$LOBO

$NXL

Motor Vehicles

Consumer Discretionary

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Nexalin Technology shares are trading higher after the company announced clinical study data in major depressive disorder and publication of clinical trial results in leading scientific journal 'Brain Stimulation'

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$NXL

Nexalin Technology shares are trading higher after the company announced clinical study data in major depressive disorder and publication of clinical trial results in leading scientific journal 'Brain Stimulation'

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$NXL

$NXL
Insider Trading

SEC Form 4 filed by CEO White Mark

SEC Form 4 filed by CFO Van Fleet Justin

SEC Form 4 filed by Chief Medical Officer Owens David

$NXL
Press Releases

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

$NXL
SEC Filings

Nexalin Technology Inc. filed SEC Form 8-K: Other Events

SEC Form 8-K filed by Nexalin Technology Inc.

SEC Form 10-Q filed by Nexalin Technology Inc.

$NXL
Insider Purchases

Sr. VP - Quality, Regulatory Shelton Carolyn Hamby bought $13,200 worth of shares (6,000 units at $2.20) (SEC Form 4)

Chief Medical Officer Owens David bought $3,100 worth of shares (1,000 units at $3.10), increasing direct ownership by 0.65% to 155,793 units (SEC Form 4)

Chief Medical Officer Owens David bought $2,980 worth of shares (1,000 units at $2.98), increasing direct ownership by 0.65% to 154,793 units (SEC Form 4)

$NXL
Leadership Updates

Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs

Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin's Next Phase of Growth and Strategic Initiatives

$NXL
Financials

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Technology shares are trading higher after the company announced clinical study data in major depressive disorder and publication of clinical trial results in leading scientific journal 'Brain Stimulation'

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $NXL

Nexalin Technology shares are trading higher after the company announced clinical study data in major depressive disorder and publication of clinical trial results in leading scientific journal 'Brain Stimulation'

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $NXL

$NXL Insider Trading

SEC Form 4 filed by CEO White Mark

SEC Form 4 filed by CFO Van Fleet Justin

SEC Form 4 filed by Chief Medical Officer Owens David

$NXL Press Releases

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

$NXL SEC Filings

Nexalin Technology Inc. filed SEC Form 8-K: Other Events

SEC Form 8-K filed by Nexalin Technology Inc.

SEC Form 10-Q filed by Nexalin Technology Inc.

$NXL Insider Purchases

Sr. VP - Quality, Regulatory Shelton Carolyn Hamby bought $13,200 worth of shares (6,000 units at $2.20) (SEC Form 4)

Chief Medical Officer Owens David bought $3,100 worth of shares (1,000 units at $3.10), increasing direct ownership by 0.65% to 155,793 units (SEC Form 4)

Chief Medical Officer Owens David bought $2,980 worth of shares (1,000 units at $2.98), increasing direct ownership by 0.65% to 154,793 units (SEC Form 4)

$NXL Leadership Updates

Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs

Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin's Next Phase of Growth and Strategic Initiatives

$NXL Financials

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Recent Analyst Ratings for
$NXL

Recent Analyst Ratings for
$NXL

$NXL
Insider Trading

$NXL
Press Releases

$NXL
SEC Filings

$NXL
Insider Purchases

$NXL
Leadership Updates

$NXL
Financials